Transplantation Research Center, Renal Division, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Avenue, Boston, MA, 02115, USA.
Infinity Pharmaceuticals, Inc 784 Memorial Drive, Cambridge, MA, 02139, USA.
Nat Commun. 2017 Oct 16;8(1):951. doi: 10.1038/s41467-017-00982-x.
Phosphatidylinositol-3-kinases (PI3K) γ and δ are preferentially enriched in leukocytes, and defects in these signaling pathways have been shown to impair T cell activation. The effects of PI3Kγ and PI3Kδ on alloimmunity remain underexplored. Here, we show that both PI3Kγ and PI3Kδ mice receiving heart allografts have suppression of alloreactive T effector cells and delayed acute rejection. However, PI3Kδ mutation also dampens regulatory T cells (Treg). After treatment with low dose CTLA4-Ig, PI3Kγ , but not PI3Κδ , recipients exhibit indefinite prolongation of heart allograft survival. PI3Kδ Tregs have increased apoptosis and impaired survival. Selective inhibition of PI3Kγ and PI3Kδ (using PI3Kδ and dual PI3Kγδ chemical inhibitors) shows that PI3Kγ inhibition compensates for the negative effect of PI3Kδ inhibition on long-term allograft survival. These data serve as a basis for future PI3K-based immune therapies for transplantation.Phosphatidylinositol-3-kinases (PI3K) γ and δ are key regulators of T cell signaling. Here the author show, using mouse heart allograft transplantation models, that PI3Kγ or PI3Kδ deficiency prolongs graft survival, but selective inhibition of PI3Kγ or PI3Kδ reveals alternative transplant survival outcomes post CTLA4-Ig treatment.
磷脂酰肌醇 3-激酶 (PI3K) γ 和 δ 优先富集于白细胞中,这些信号通路的缺陷已被证明会损害 T 细胞的激活。PI3Kγ 和 PI3Kδ 对同种异体免疫的影响仍未得到充分探索。在这里,我们表明接受心脏同种异体移植物的 PI3Kγ 和 PI3Kδ 小鼠均抑制了同种反应性 T 效应细胞并延迟了急性排斥反应。然而,PI3Kδ 突变也会抑制调节性 T 细胞(Treg)。在用低剂量 CTLA4-Ig 治疗后,PI3Kγ ,但不是 PI3Κδ ,受体会出现心脏同种异体移植物存活的无限期延长。PI3Kδ Treg 细胞凋亡增加,存活率降低。选择性抑制 PI3Kγ 和 PI3Kδ(使用 PI3Kδ 和双重 PI3Kγδ 化学抑制剂)表明 PI3Kγ 抑制可补偿 PI3Kδ 抑制对长期同种异体移植物存活的负面影响。这些数据为未来基于 PI3K 的移植免疫疗法提供了依据。磷脂酰肌醇 3-激酶 (PI3K) γ 和 δ 是 T 细胞信号转导的关键调节剂。在这里,作者使用小鼠心脏同种异体移植模型表明,PI3Kγ 或 PI3Kδ 缺乏可延长移植物存活期,但选择性抑制 PI3Kγ 或 PI3Kδ 在 CTLA4-Ig 治疗后揭示了替代的移植存活结果。